... important to the patient’s health, and must often be performed. As the plan is implemented, we must ensure that patients who need life-saving care can receive it. We thank the White House task force for working with AdvaMed, our member companies who manufacture these ...

... crucial surgical technologies, and the health care professionals who helped make the case that we need to work responsibly to get these patients the care they need.

There comes a moment when elective care becomes essential and I believe we can’t forget about our non-COVID19 patients. Great piece on the same by Lisa Rosenbaum in NEJM. nejm.org/doi/full/10.10…

Important milestone! Congrats to the great team at Personal Genome Diagnostics (PGDx)

SubjectWell Recruits Patients for COVID-19 Vaccine Clinical Trials, Works to Address Lack of Racial Diversity in Patient Recruitment To Date subjectwell.com/news/subjectwe…

Personal Genome Diagnostics Announces Medicare Coverage of PGDx elio™ tissue complete Assay for Patients with Advanced Cancer | Business Wire businesswire.com/news/home/2020…

purewow.com/family/willow-…

Excited to share that #CMS has approved Transitional Pass-Through (TPT) payment for CVRx #Barostim for #heartfailure! TPT will be effective Jan 1 2021 and provide incremental reimbursement in the outpatient setting! #EPeeps #Cardiotwitter PR: bit.ly/3mHLNHa

Finalists Selected in $6 Million XPRIZE Rapid Covid Testing Competition to Help Restart Global Economy | Business Wire businesswire.com/news/home/2020…

Excited to have helped seed Delfi and partner w/Victor Velculescu, great things to come: Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biops... prn.to/3bwiW5P

Excited to share that CVRx has been named to the #Fierce15 this year! We are honored that Fierce Medtech sees the potential for #Barostim to become an important therapy to treat #heartfailure symptoms. Please see the article & interview with Nadim Yared fiercebiotech.com/special-report…

Great accomplishment! ChromaCode, Inc. Selected as a Winner of $6M XPRIZE Rapid COVID Testing Competition prn.to/3eX6nm3

Who will make the vaccine next time?

Today we announce something BIG that will help us continue on our mission to revolutionize by-the-glass consumption of #Champagne and #SparklingWine. 🥂 Drumroll, please.... bit.ly/3DubSld

Proud to announce our new look at Windham Venture Partners We support healthcare through life saving, game changing investing, partnering with founders and leaders building innovative healthtech solutions. Here's to helping great people build great companies. windhamvp.com

Congrats to DELFI Diagnostics on their $225M Series B financing! We are proud to take part in this funding to support the continued development and commercialization of high-quality blood tests early cancer detection and treatment monitoring. tinyurl.com/ys53hm3u

Congratulations to Windham portfolio company, Upward Health, on being awarded the ACO REACH model contract by CMS. This contract paves the way for Upward to continue to offer services to individuals with complex needs while reducing costs. businesswire.com/news/home/2022…

We are excited to announce our investment in Vergent Bioscience's $21.5M Series B raise. Vergent is an innovative medical technology company developing an agent for the visualization of tumor tissue during cancer resections. Read about why we invested here: tinyurl.com/vergentinvestm…